54 research outputs found
Mincle polarizes human monocyte and neutrophil responses to Candida albicans
The distribution and function of the C-type lectin Mincle has not previously been investigated in human cells, although mouse models have demonstrated a non-redundant role for Mincle in the host response to fungal infections. This study identified an unusual pattern of reciprocal expression of Mincle on peripheral blood monocytes or neutrophils isolated from the same donor. Expression on monocytes was inversely correlated with phagocytosis and yeast killing, but was necessary for the induction of inflammatory cytokines in response to ex vivo Candida challenge. In contrast, Mincle expression on neutrophils was associated with phagocytic and candidacidal potential of those cells. Candida challenge upregulated Mincle expression but only in Mincle+ cells. These data highlight species-specific differences between the regulation of Mincle expression in mouse and man. Reciprocal expression of Mincle modified the candidacidal potential of monocytes or neutrophils, suggesting it may also polarize the type of host response to fungal infection. Immunology and Cell Biology (2012) 90, 889-895; doi:10.1038/icb.2012.24; published online 29 May 201
Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naĂŻve and memory WT1âspecific CD8+ T cells
Objectives
Vaccines that prime Wilms' tumor 1 (WT1)âspecific CD8+ T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141+ dendritic cells (DCs). The Câtype lectinâlike receptor CLEC9A is expressed exclusively by CD141+ DCs and regulates CD8+ Tâcell responses. We developed a new vaccine comprising a human antiâCLEC9A antibody fused to WT1 and investigated its capacity to target human CD141+ DCs and activate naĂŻve and memory WT1âspecific CD8+ T cells.
Methods
WT1 was genetically fused to antibodies specific for human CLEC9A, DECâ205 or ÎČâgalactosidase (untargeted control). Activation of WT1âspecific CD8+ Tâcell lines following crossâpresentation by CD141+ DCs was quantified by IFNÎł ELISPOT. Humanised mice reconstituted with human immune cell subsets, including a repertoire of naĂŻve WT1âspecific CD8+ T cells, were used to investigate naĂŻve WT1âspecific CD8+ Tâcell priming.
Results
The CLEC9AâWT1 vaccine promoted crossâpresentation of WT1 epitopes to CD8+ T cells and mediated priming of naĂŻve CD8+ T cells more effectively than the DECâ205âWT1 and untargeted controlâWT1 vaccines.
Conclusions
Delivery of WT1 to CD141+ DCs via CLEC9A stimulates CD8+ T cells more potently than either untargeted delivery or widespread delivery to all Agâpresenting cells via DECâ205, suggesting that crossâpresentation by CD141+ DCs is sufficient for effective CD8+ Tâcell priming in humans. The CLEC9AâWT1 vaccine is a promising candidate immunotherapy for malignancies that express WT1
Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease
Allogeneic (allo) hematopoietic stem cell transplantation is an effective therapy for hematological malignancies but it is limited by acute graft-versus-host disease (GVHD). Dendritic cells (DC) play a major role in the allo T cell stimulation causing GVHD. Current immunosuppressive measures to control GVHD target T cells but compromise posttransplant immunity in the patient, particularly to cytomegalovirus (CMV) and residual malignant cells. We showed that treatment of allo mixed lymphocyte cultures with activated human DC-depleting CD83 antibody suppressed alloproliferation but preserved T cell numbers, including those specific for CMV. We also tested CD83 antibody in the human T cellâdependent peripheral blood mononuclear cell transplanted SCID (hu-SCID) mouse model of GVHD. We showed that this model requires human DC and that CD83 antibody treatment prevented GVHD but, unlike conventional immunosuppressants, did not prevent engraftment of human T cells, including cytotoxic T lymphocytes (CTL) responsive to viruses and malignant cells. Immunization of CD83 antibody-treated hu-SCID mice with irradiated human leukemic cell lines induced allo antileukemic CTL effectors in vivo that lysed 51Cr-labeled leukemic target cells in vitro without further stimulation. Antibodies that target activated DC are a promising new therapeutic approach to the control of GVHD
T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex
Central to adaptive immunity is the interaction between the αÎČ T cell receptor (TCR) and peptide presented by the major histocompatibility complex (MHC) molecule. Presumably reflecting TCR-MHC bias and T cell signaling constraints, the TCR universally adopts a canonical polarity atop the MHC. We report the structures of two TCRs, derived from human induced T regulatory (iTreg) cells, complexed to an MHC class II molecule presenting a proinsulin-derived peptide. The ternary complexes revealed a 180° polarity reversal compared to all other TCR-peptide-MHC complex structures. Namely, the iTreg TCR α-chain and ÎČ-chain are overlaid with the α-chain and ÎČ-chain of MHC class II, respectively. Nevertheless, this TCR interaction elicited a peptide-reactive, MHC-restricted T cell signal. Thus TCRs are not 'hardwired' to interact with MHC molecules in a stereotypic manner to elicit a T cell signal, a finding that fundamentally challenges our understanding of TCR recognition
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens
The characterization of human dendritic cell (DC) subsets is essential for the design of new vaccines. We report the first detailed functional analysis of the human CD141+ DC subset. CD141+ DCs are found in human lymph nodes, bone marrow, tonsil, and blood, and the latter proved to be the best source of highly purified cells for functional analysis. They are characterized by high expression of toll-like receptor 3, production of IL-12p70 and IFN-ÎČ, and superior capacity to induce T helper 1 cell responses, when compared with the more commonly studied CD1c+ DC subset. Polyinosine-polycytidylic acid (poly I:C)âactivated CD141+ DCs have a superior capacity to cross-present soluble protein antigen (Ag) to CD8+ cytotoxic T lymphocytes than poly I:Câactivated CD1c+ DCs. Importantly, CD141+ DCs, but not CD1c+ DCs, were endowed with the capacity to cross-present viral Ag after their uptake of necrotic virus-infected cells. These findings establish the CD141+ DC subset as an important functionally distinct human DC subtype with characteristics similar to those of the mouse CD8α+ DC subset. The data demonstrate a role for CD141+ DCs in the induction of cytotoxic T lymphocyte responses and suggest that they may be the most relevant targets for vaccination against cancers, viruses, and other pathogens
Recommended from our members
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis
Multifactorial mechanisms underlying late-onset Alzheimer's disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-ÎČ deposition, metabolism, vascular, functional activity at rest, structural properties, cognitive integrity and peripheral proteins levels are characterized in relation to LOAD progression. We analyse over 7,700 brain images and tens of plasma and cerebrospinal fluid biomarkers from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Through a multifactorial data-driven analysis, we obtain dynamic LOADâabnormality indices for all biomarkers, and a tentative temporal ordering of disease progression. Imaging results suggest that intra-brain vascular dysregulation is an early pathological event during disease development. Cognitive decline is noticeable from initial LOAD stages, suggesting early memory deficit associated with the primary disease factors. High abnormality levels are also observed for specific proteins associated with the vascular system's integrity. Although still subjected to the sensitivity of the algorithms and biomarkers employed, our results might contribute to the development of preventive therapeutic interventions
Dendritic cells in autoimmune disease
Dendritic cells (DC) are a group of sparsely distributed "professional" antigen presenting cells. Most DC are relatively short-lived cells that must be continually renewed by precursors from bone marrow. Their characteristic form led to their recognition as a distinct cell type by Steinman and Cohn in 1973. Subsequent work revealed their key function in the adaptive immune system: the collection, processing, and presentation of peptide fragments of antigens to T cells on major histocompatibility complex (MHC) molecules. The exceptional ability of DC to process and present antigens and so to activate even naĂŻve T cells has endowed them with the title of "professional" antigen presenting cells. In steady state DC play a role in lymphocyte specificity selection and the maintenance of peripheral tolerance. However, DC serve as the sentinels of the immune system and are rapidly activated, via innate response mechanisms, by pathogens or host factors that signal danger or stress. Activated DC produce cytokines and other factors that contribute to inflammatory responses. Upon activation those sentinel DC in peripheral tissues migrate to lymph nodes to allow contact with T cells. The activated DC presenting antigen-MHC complexes then activate antigen-specific T cells to initiate immune responses. The nature of the subsequent response is in part determined by factors produced by the DC. DC thus link the innate and the adaptive immune systems.DC constitute 1% or less of the cells in various tissues of the body. Different types of DC occur in different anatomical locations and even within one location. These DC subsets differ in surface phenotype and in specialized aspects of DC function. This diversity of DC subsets is key to obtaining the appropriate immunological response to different pathogen challenges. However, together with the low number of DC it presents a daunting obstacle to determining the role of DC in human disease. This chapter aims to address the functional aspects of different types of DC relevant to autoimmunity, with specific examples of functions contributing to autoimmune disease etiology
Can Dendritic Cell vaccination prevent leukemia relapse?
Leukemias are clonal proliferative disorders arising from immature leukocytes in the bone marrow. While the advent of targeted therapies has improved survival in certain subtypes, relapse after initial therapy is a major problem. Dendritic cell (DC) vaccination has the potential to induce tumor-specific T cells providing long-lasting, anti-tumor immunity. This approach has demonstrated safety but limited clinical success until recently, as DC vaccination faces several barriers in both solid and hematological malignancies. Importantly, vaccine-mediated stimulation of protective immune responses is hindered by the aberrant production of immunosuppressive factors by cancer cells which impede both DC and T cell function. Leukemias present the additional challenge of severely disrupted hematopoiesis owing to both cytogenic defects in hematopoietic progenitors and an abnormal hematopoietic stem cell niche in the bone marrow; these factors accentuate systemic immunosuppression and DC malfunction. Despite these obstacles, several recent clinical trials have caused great excitement by extending survival in Acute Myeloid Leukemia (AML) patients through DC vaccination. Here, we review the phenotype and functional capacity of DCs in leukemia and approaches to harness DCs in leukemia patients. We describe the recent clinical successes in AML and detail the multiple new strategies that might enhance prognosis in AML and other leukemias
- âŠ